Cargando...

The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies

PURPOSE: A secondary epidermal growth factor receptor (EGFR) mutation, T790M, is the most common resistance mechanism in EGFR mutant adenocarcinomas that have progressed on erlotinib. Third generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Niederst, Matthew J., Hu, Haichuan, Mulvey, Hillary E., Lockerman, Elizabeth L., Garcia, Angel R., Piotrowska, Zofia, Sequist, Lecia V., Engelman, Jeffrey A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4587765/
https://ncbi.nlm.nih.gov/pubmed/25964297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0560
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!